BIO-TECHNE Corp (NASDAQ:TECH) Given Consensus Recommendation of “Hold” by Brokerages

BIO-TECHNE Corp (NASDAQ:TECH) has been given an average rating of “Hold” by the twelve analysts that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $238.33.

A number of research analysts have recently commented on the stock. Wells Fargo & Co assumed coverage on shares of BIO-TECHNE in a research report on Tuesday, January 7th. They issued an “equal weight” rating and a $230.00 price objective for the company. Citigroup decreased their price objective on shares of BIO-TECHNE from $235.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. Robert W. Baird lifted their price objective on shares of BIO-TECHNE from $222.00 to $230.00 and gave the company an “outperform” rating in a research report on Wednesday, February 5th. Zacks Investment Research downgraded shares of BIO-TECHNE from a “hold” rating to a “strong sell” rating in a research report on Saturday, February 8th. Finally, TheStreet raised shares of BIO-TECHNE from a “c+” rating to a “b-” rating in a research report on Wednesday, November 27th.

In other news, Director Roeland Nusse sold 8,347 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $219.33, for a total transaction of $1,830,747.51. Following the completion of the sale, the director now owns 15,721 shares in the company, valued at approximately $3,448,086.93. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Charles R. Kummeth sold 10,276 shares of BIO-TECHNE stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $217.28, for a total transaction of $2,232,769.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,313 shares of company stock valued at $14,482,152. 4.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of TECH. Candriam Luxembourg S.C.A. raised its stake in BIO-TECHNE by 20.2% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 129,857 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 21,840 shares in the last quarter. Lenox Wealth Advisors LLC bought a new position in BIO-TECHNE in the 4th quarter valued at about $33,000. Flagship Harbor Advisors LLC increased its holdings in BIO-TECHNE by 96.2% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 255 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 125 shares during the period. Quest Capital Management Inc. ADV bought a new position in BIO-TECHNE in the 3rd quarter valued at about $54,000. Finally, Parallel Advisors LLC increased its holdings in BIO-TECHNE by 119.5% in the 4th quarter. Parallel Advisors LLC now owns 248 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 135 shares during the period. Institutional investors and hedge funds own 93.25% of the company’s stock.

BIO-TECHNE stock traded up $2.88 during mid-day trading on Friday, reaching $208.53. The company’s stock had a trading volume of 75,580 shares, compared to its average volume of 162,669. The business’s 50 day simple moving average is $214.29 and its 200 day simple moving average is $206.65. BIO-TECHNE has a 12 month low of $178.28 and a 12 month high of $223.29. The company has a market capitalization of $8.00 billion, a price-to-earnings ratio of 42.04, a price-to-earnings-growth ratio of 4.49 and a beta of 1.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 3.52 and a current ratio of 4.43.

BIO-TECHNE (NASDAQ:TECH) last announced its quarterly earnings data on Tuesday, February 4th. The biotechnology company reported $1.08 EPS for the quarter, missing analysts’ consensus estimates of $1.13 by ($0.05). BIO-TECHNE had a net margin of 26.20% and a return on equity of 12.45%. The firm had revenue of $184.93 million during the quarter, compared to the consensus estimate of $191.34 million. During the same period last year, the business earned $1.06 EPS. The business’s revenue was up 6.0% on a year-over-year basis. As a group, sell-side analysts expect that BIO-TECHNE will post 4.16 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Stockholders of record on Friday, February 14th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Thursday, February 13th. BIO-TECHNE’s dividend payout ratio is presently 33.68%.

About BIO-TECHNE

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

See Also: What are the benefits of a portfolio tracker?

Analyst Recommendations for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.